Myelodysplastic Syndrome - Global Clinical Trials Review, 2025
Summary
GlobalData's clinical trial report, “Myelodysplastic Syndrome - Global Clinical Trials Review, 2025 provides an overview of Myelodysplastic Syndrome Clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
- Report Guidance
- GlobalData Clinical Trials Report Coverage
- Clinical Trials by Region
- Clinical Trials and Average Enrollment by Country
- Top Five Countries Contributing to Clinical Trials in Asia-Pacific
- Top Five Countries Contributing to Clinical Trials in Europe
- Top Countries Contributing to Clinical Trials in North America
- Top Five Countries Contributing to Clinical Trials in Middle East and Africa
- Top Five Countries Contributing to Clinical Trials in Central and South America
- Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
- Clinical Trials by Phase in G7 Countries
- Clinical Trials in G7 Countries by Trial Status
- Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials
- Clinical Trials by Phase in E7 Countries
- Clinical Trials in E7 Countries by Trial Status
- Clinical Trials by Phase
- In Progress Trials by Phase
- Clinical Trials by Trial Status
- Clinical Trials by End Point Status
- Subjects Recruited Over a Period of Time
- Clinical Trials by Sponsor Type
- Prominent Sponsors
- Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials
- Prominent Drugs
- Latest Clinical Trials News on Myelodysplastic Syndrome
- Jan 23, 2025: Oryzon Announces First Patient Dosed in an Investigator-Initiated Phase I Study of Iadademstat in Myelodysplastic Syndrome
- Jan 09, 2025: Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
- Dec 12, 2024: Kind Presents Preclinical Results of AND017 at the 66th ASH and Exposition and Announces FDA Authorization of IND Application for AND017 in SCD
- Dec 10, 2024: Live from Ash 2024 | Ascentage Pharma Releases Data of Bcl-2 Inhibitor Lisaftoclax in Mds That Demonstrates Potential Benefits and Favorable Safety
- Dec 10, 2024: Geron Announces New Imerge Analyses Presented at Ash Suggesting Clinical Activity of Rytelo (Imetelstat) in Patients with Lower-Risk Mds
- Dec 10, 2024: Faron presents BEXMAB data at ASH Annual Meeting
- Dec 10, 2024: Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with LR-MDS
- Dec 09, 2024: PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting
- Dec 09, 2024: Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition
- Dec 09, 2024: Keros Presents Clinical Data from its Elritercept Program at the 66th American Society of Hematology Annual Meeting and Exposition
- Dec 09, 2024: Taiho Oncology Data at ASH Annual Meeting Highlight Progress in Oral Therapies for Patients with Blood Cancers
- Dec 08, 2024: Orca Bio Presents Three-Year Survival Data with Orca-T in Patients with Hematological Malignancies at the 66th ASH Annual Meeting
- Dec 05, 2024: Simcha Therapeutics Announces the Opening of Two Clinical Studies Exploring ST-067 in Hematological Indications
- Dec 04, 2024: Flamingo Therapeutics Announces Poster Presentation on Aml Phase 1 IIT Study at Ash 2024
- Dec 02, 2024: Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
- Nov 12, 2024: Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
- Nov 05, 2024: Keros Therapeutics to Present at the 66th American Society of Hematology Annual Meeting and Exposition
- Nov 05, 2024: Rigel Announces Poster Presentations on R-289 at the 66th American Society of Hematology Annual Meeting and Exposition
- Nov 05, 2024: Taiho Oncology to Present Data at the 66th American Society of Hematology Annual Meeting
- Nov 05, 2024: Orca Bio to Present Clinical Data on Orca-T at the 66th American Society of Hematology Annual Meeting
- Nov 05, 2024: Tscan Therapeutics Announces Upcoming Oral Presentation of Data from the TSC-100 at the 66th ASH Annual Meeting and Exposition
- Nov 05, 2024: Tscan Therapeutics Announces Upcoming Oral Presentation of Data from the TSC-101 at the 66th ASH Annual Meeting and Exposition
- Clinical Trial Profile Snapshots
- Abbreviations
- Definitions
- Research Methodology
- Secondary Research
- About GlobalData
- Contact Us
- Disclaimer
- Source
- List of Tables
- Table 1: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2025*
- Table 2: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Table 3: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Table 4: Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2025*
- Table 5: Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2025*
- Table 6: Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2025*
- Table 7: Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2025*
- Table 8: Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2025*
- Table 9: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2025*
- Table 10: Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Table 11: Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Table 12: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2025*
- Table 13: Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Table 14: Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Table 15: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2025*
- Table 16: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2025*
- Table 17: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Table 18: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Table 19: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Table 20: Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2025*
- Table 21: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Table 22: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Table 23: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- List of Figures
- Figure 1: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2025*
- Figure 2: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2025*
- Figure 3: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2025*
- Figure 4: Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2025*
- Figure 5: Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2025*
- Figure 6: Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2025*
- Figure 7: Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2025*
- Figure 8: Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2025*
- Figure 9: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2025*
- Figure 10: Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2025*
- Figure 11: Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2025*
- Figure 12: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2025*
- Figure 13: Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2025*
- Figure 14: Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2025*
- Figure 15: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2025*
- Figure 16: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2025*
- Figure 17: Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2025*
- Figure 18: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2025*
- Figure 19: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2020-2024
- Figure 20: Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2025*
- Figure 21: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2025*
- Figure 22: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2025*
- Figure 23: Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2025*
- Figure 24: GlobalData Methodology
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook